Compounded Semaglutide vs Wegovy®: Which Should You Choose?

A few years ago, the choice was simple: if you wanted semaglutide, you took Wegovy® or Ozempic® — both made by Novo Nordisk and priced accordingly. Then came the drug shortage. The FDA's shortage list opened a legal pathway for compounding pharmacies to produce semaglutide, and suddenly a $1,300/month medication became available for $199/month.

But what exactly is compounded semaglutide? Is it the same? Is it as safe? And which option is right for you? Here's the complete breakdown.

What Is Compounded Semaglutide?

Compounded semaglutide is semaglutide prepared by a 503B-licensed outsourcing facility — a federally regulated category of compounding pharmacy that operates under FDA oversight and must comply with current Good Manufacturing Practice (cGMP) standards.

Key characteristics of compounded semaglutide:

• Same active ingredient: Contains semaglutide, the identical active molecule found in Wegovy® and Ozempic®
• Customizable dosing: Can be prepared in various concentrations to support precise, individualized titration schedules
• Not FDA-approved as a finished drug product: The compound itself hasn't undergone FDA's new drug approval process, though the active ingredient is FDA-approved and the facility is FDA-registered
• Third-party tested: Reputable 503B pharmacies submit products to independent labs for potency and purity testing
• Prescribed by licensed physicians: Available only through a valid prescription from a licensed provider

What Is Wegovy®?

Wegovy® is the brand-name, FDA-approved formulation of semaglutide for chronic weight management, manufactured by Novo Nordisk. It was approved by the FDA in June 2021 based on the STEP clinical trials and has been the gold standard for GLP-1-based weight management since.

Wegovy® comes in pre-filled auto-injector pens in fixed doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg — designed for a specific 16-week titration schedule. It is dispensed through retail pharmacies with a prescription and has the full weight of FDA regulatory oversight behind it.

Key Differences at a Glance

Safety: Is Compounded Semaglutide Safe?

This is the most common question — and it deserves a thorough, honest answer.

The Case For Safety

• 503B compounding facilities are federally regulated and subject to FDA inspections
• Third-party potency and sterility testing ensures the active ingredient is present at labeled concentration
• The active molecule (semaglutide) is identical to what's in Wegovy® — extensive human safety data exists for this molecule
• Millions of patients have used compounded semaglutide without serious safety signals beyond those expected for the class

The Case for Caution

• Without FDA approval for the finished product, there is no formal agency review of bioequivalence
• Quality can vary between compounding pharmacies — this is why choosing a reputable 503B facility matters enormously
• The FDA has issued warnings about some low-quality compounders and gray-market semaglutide products. Always use a pharmacy partner of a licensed telehealth provider like Truventa Medical

Bottom line: Compounded semaglutide from a reputable 503B pharmacy, prescribed by a licensed physician, has a well-established safety record. The key differentiator is who is compounding it and under what quality controls.

Truventa Medical uses only 503B-licensed facilities with demonstrated quality testing records. We do not work with unverified or gray-market suppliers.

Efficacy: Is It as Effective as Wegovy®?

Because compounded semaglutide contains the same active molecule at the same doses as Wegovy®, the mechanism of action is identical. From a pharmacological standpoint, equivalent doses of semaglutide should produce equivalent clinical effects.

The clinical evidence supporting semaglutide's efficacy — the STEP trials showing 14.9% average weight loss — was conducted with Novo Nordisk's formulation. There are no large-scale head-to-head trials comparing compounded to brand-name semaglutide. However, the fundamental principle of pharmaceutical compounding is that equivalent active ingredient at equivalent concentration produces equivalent biological activity.

Many thousands of patients have achieved substantial weight loss on compounded semaglutide through telehealth providers, consistent with the results seen in clinical trials.

The Wegovy Savings Card Option

Novo Nordisk offers a savings card program for Wegovy® that can significantly reduce cost for eligible patients. Under this program:

• Commercially insured patients with a qualifying plan may pay as little as $0/month
• Patients without insurance coverage may qualify for a reduced price through the NovoCare program
• The savings program does not apply to Medicare or Medicaid beneficiaries

If you have excellent commercial insurance that covers obesity medications, Wegovy® with the savings card may be competitive with compounded pricing. However, many insurance plans still do not cover obesity medications at all, making compounded options significantly more accessible.

When to Choose Compounded Semaglutide

A Note on the FDA's Evolving Position

It's worth noting that the FDA's allowance for compounding semaglutide was tied to the drug shortage designation. As supply of brand-name semaglutide has improved, the regulatory landscape around compounding can evolve. Truventa Medical monitors all regulatory developments and will keep patients informed of any changes that affect their treatment options.

As of April 2026, compounded semaglutide remains legally available through licensed telehealth providers working with 503B facilities.